Selected research
Market Structure
Global Furazolidone Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Furazolidone market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Furazolidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Furazolidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Furazolidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Furazolidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Furazolidone include Becton, Dickinson and Company (BD), Daiichi Sankyo, Ferring, Geo-Med, GrÜNenthal Gmbh, Keyfarm, KPL Pharma, Marvi and Standpharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Furazolidone market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Furazolidone and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Furazolidone sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Furazolidone market size, projected growth trends, production technologies, key applications, and end-use industries.
Furazolidone Segment by Company
Becton, Dickinson and Company (BD)
Daiichi Sankyo
Ferring
Geo-Med
GrÜNenthal Gmbh
Keyfarm
KPL Pharma
Marvi
Standpharm
Teva
Furazolidone Segment by Type
Pharma Grade
Industrial Grade
Others
Furazolidone Segment by Application
Pharmacy
Industry
Furazolidone Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Furazolidone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Furazolidone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Furazolidone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Furazolidone market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Furazolidone manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Furazolidone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Furazolidone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Pharma Grade
- Industrial Grade
- Others
Applications
- Pharmacy
- Industry
Companies covered
- Becton, Dickinson and Company (BD)
- Daiichi Sankyo
- Ferring
- Geo-Med
- GrÜNenthal Gmbh
- Keyfarm
- KPL Pharma
- Marvi
- Standpharm
- Teva
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Furazolidone Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Furazolidone Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Furazolidone Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Furazolidone Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Furazolidone Market Dynamics
- 2.1 Furazolidone Industry Trends
- 2.2 Furazolidone Industry Drivers
- 2.3 Furazolidone Industry Opportunities and Challenges
- 2.4 Furazolidone Industry Restraints
3 Furazolidone Market by Manufacturers
- 3.1 Global Furazolidone Revenue by Manufacturers (2021-2026)
- 3.2 Global Furazolidone Sales by Manufacturers (2021-2026)
- 3.3 Global Furazolidone Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Furazolidone Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Furazolidone Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Furazolidone Manufacturers, Product Type & Application
- 3.7 Global Furazolidone Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Furazolidone Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Furazolidone Players Market Share by Revenue in 2025
- 3.8.3 2025 Furazolidone Tier 1, Tier 2, and Tier 3
4 Furazolidone Market by Type
- 4.1 Furazolidone Type Introduction
- 4.1.1 Pharma Grade
- 4.1.2 Industrial Grade
- 4.1.3 Others
- 4.2 Global Furazolidone Sales by Type
- 4.2.1 Global Furazolidone Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Furazolidone Sales by Type (2021-2032)
- 4.2.3 Global Furazolidone Sales Market Share by Type (2021-2032)
- 4.3 Global Furazolidone Revenue by Type
- 4.3.1 Global Furazolidone Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Furazolidone Revenue by Type (2021-2032)
- 4.3.3 Global Furazolidone Revenue Market Share by Type (2021-2032)
5 Furazolidone Market by Application
- 5.1 Furazolidone Application Introduction
- 5.1.1 Pharmacy
- 5.1.2 Industry
- 5.2 Global Furazolidone Sales by Application
- 5.2.1 Global Furazolidone Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Furazolidone Sales by Application (2021-2032)
- 5.2.3 Global Furazolidone Sales Market Share by Application (2021-2032)
- 5.3 Global Furazolidone Revenue by Application
- 5.3.1 Global Furazolidone Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Furazolidone Revenue by Application (2021-2032)
- 5.3.3 Global Furazolidone Revenue Market Share by Application (2021-2032)
6 Global Furazolidone Sales by Region
- 6.1 Global Furazolidone Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Furazolidone Sales by Region (2021-2032)
- 6.2.1 Global Furazolidone Sales by Region (2021-2026)
- 6.2.2 Global Furazolidone Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Furazolidone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Furazolidone Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Furazolidone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Furazolidone Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Furazolidone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Furazolidone Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Furazolidone Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Furazolidone Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Furazolidone Revenue by Region
- 7.1 Global Furazolidone Revenue by Region
- 7.1.1 Global Furazolidone Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Furazolidone Revenue by Region (2021-2026)
- 7.1.3 Global Furazolidone Revenue by Region (2027-2032)
- 7.1.4 Global Furazolidone Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Furazolidone Revenue (2021-2032)
- 7.2.2 North America Furazolidone Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Furazolidone Revenue (2021-2032)
- 7.3.2 Europe Furazolidone Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Furazolidone Revenue (2021-2032)
- 7.4.2 Asia-Pacific Furazolidone Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Furazolidone Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Furazolidone Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Becton, Dickinson and Company (BD)
- 8.1.1 Becton, Dickinson and Company (BD) Company Information
- 8.1.2 Becton, Dickinson and Company (BD) Business Overview
- 8.1.3 Becton, Dickinson and Company (BD) Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Becton, Dickinson and Company (BD) Furazolidone Product Portfolio
- 8.1.5 Becton, Dickinson and Company (BD) Recent Developments
- 8.2 Daiichi Sankyo
- 8.2.1 Daiichi Sankyo Company Information
- 8.2.2 Daiichi Sankyo Business Overview
- 8.2.3 Daiichi Sankyo Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Daiichi Sankyo Furazolidone Product Portfolio
- 8.2.5 Daiichi Sankyo Recent Developments
- 8.3 Ferring
- 8.3.1 Ferring Company Information
- 8.3.2 Ferring Business Overview
- 8.3.3 Ferring Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Ferring Furazolidone Product Portfolio
- 8.3.5 Ferring Recent Developments
- 8.4 Geo-Med
- 8.4.1 Geo-Med Company Information
- 8.4.2 Geo-Med Business Overview
- 8.4.3 Geo-Med Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Geo-Med Furazolidone Product Portfolio
- 8.4.5 Geo-Med Recent Developments
- 8.5 GrÜNenthal Gmbh
- 8.5.1 GrÜNenthal Gmbh Company Information
- 8.5.2 GrÜNenthal Gmbh Business Overview
- 8.5.3 GrÜNenthal Gmbh Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 GrÜNenthal Gmbh Furazolidone Product Portfolio
- 8.5.5 GrÜNenthal Gmbh Recent Developments
- 8.6 Keyfarm
- 8.6.1 Keyfarm Company Information
- 8.6.2 Keyfarm Business Overview
- 8.6.3 Keyfarm Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Keyfarm Furazolidone Product Portfolio
- 8.6.5 Keyfarm Recent Developments
- 8.7 KPL Pharma
- 8.7.1 KPL Pharma Company Information
- 8.7.2 KPL Pharma Business Overview
- 8.7.3 KPL Pharma Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 KPL Pharma Furazolidone Product Portfolio
- 8.7.5 KPL Pharma Recent Developments
- 8.8 Marvi
- 8.8.1 Marvi Company Information
- 8.8.2 Marvi Business Overview
- 8.8.3 Marvi Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Marvi Furazolidone Product Portfolio
- 8.8.5 Marvi Recent Developments
- 8.9 Standpharm
- 8.9.1 Standpharm Company Information
- 8.9.2 Standpharm Business Overview
- 8.9.3 Standpharm Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Standpharm Furazolidone Product Portfolio
- 8.9.5 Standpharm Recent Developments
- 8.10 Teva
- 8.10.1 Teva Company Information
- 8.10.2 Teva Business Overview
- 8.10.3 Teva Furazolidone Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Teva Furazolidone Product Portfolio
- 8.10.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Furazolidone Value Chain Analysis
- 9.1.1 Furazolidone Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Furazolidone Production Mode & Process
- 9.2 Furazolidone Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Furazolidone Distributors
- 9.2.3 Furazolidone Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst